To date, there is a plethora of literature relating to the metabolic benefits of GLP-1 receptor activation, highlighted by the clinical approval of GLP-1 mimetics for both type 2 diabetes and obesity [7,8]. This evidence concerns the gene GCG and obesity disorder.